ReviewCells2020
Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 89 citations in OpenAlex.
- Age-driven shifts in T and NK cell responses amplify inflammation and coagulopathy during viral infection in mice and humans.Frontiers in immunology · 2026Article
- COVID-19 and female reproductive health: pathophysiological mechanisms and clinical reproductive outcomes.Frontiers in medicine · 2026Review
- Comparative histopathologic analysis of COVID-19-associated pseudo-chilblains ("COVID-toes"), with idiopathic pernio, and chilblains lupus erythematosus.JAAD international · 2025Article
- The dynamic role of soluble urokinase plasminogen activator receptor (suPAR) in monitoring coagulation dysfunction during COVID-19 progression: a review.Annals of medicine and surgery (2012) · 2025Review
- The causal association between COVID-19 and ischemic stroke: a mendelian randomization study.Virology journal · 2024Article
- Vascular Alterations Following COVID-19 Infection: A Comprehensive Literature Review.Life (Basel, Switzerland) · 2024Review
- The Effect of Coronavirus Disease 2019 on the Quality of Associated Care in Patients with Gastric Cancer.Middle East journal of digestive diseases · 2024Review
- Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke.Frontiers of medicine · 2023Review
- Pathways of Coagulopathy and Inflammatory Response in SARS-CoV-2 Infection among Type 2 Diabetic Patients.International journal of molecular sciences · 2023Review
- SARS-CoV-2 Possible Etiology of Cerebral Venous Thrombosis in a Teenager: Case Report and Review of Literature.Viruses · 2023Review
- The impact of COVID-19 on clinical outcomes of burn patients.Burns & trauma · 2023Article
- Thromboembolism in the Complications of Long COVID-19.Cardiology and cardiovascular medicine · 2023Article
- Neurological effects of COVID-19 in infants and children.Developmental medicine and child neurology · 2022Review
- [Anticoagulation in coronavirus disease 2019 (COVID-19): confirmed and controversial aspects].Der Internist · 2022Review
- Does COVID-19 infection increase the risk of pressure injury in critically ill patients?: A narrative review.Medicine · 2022Review
- Risk factors and severity of functional impairment in long COVID: a single-center experience in Croatia.Croatian medical journal · 2022Article
- Vitamin D Inhibits IL-6 Pro-Atherothrombotic Effects in Human Endothelial Cells: A Potential Mechanism for Protection against COVID-19 Infection?Journal of cardiovascular development and disease · 2022Article
- Neurological Aspects of the Sequelae of COVID-19 in Children.Neuroscience and behavioral physiology · 2022Article
- SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies.International immunopharmacology · 2021Review
- Bioactive Molecules Derived from Snake Venoms with Therapeutic Potential for the Treatment of Thrombo-Cardiovascular Disorders Associated with COVID-19.The protein journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in > 500,000 deaths worldwide, including > 125,000 deaths in the U.S. since its emergence in late December 2019 and June 2020. Neither curative anti-viral drugs nor a protective vaccine is currently available for the treatment and prevention of COVID-19. Recently, new clinical syndromes associated with coagulopathy and vasculopathy have emerged as a cause of sudden death and other serious clinical manifestations in younger patients infected with SARS-CoV-2 infection. Angiotensin converting enzyme 2 (ACE2), the receptor for SARS-CoV-2 and other coronaviruses, is a transmembrane protein expressed by lung alveolar epithelial cells, enterocytes, and vascular endothelial cells, whose physiologic role is to induce the maturation of angiotensin I to generate angiotensin 1-7, a peptide hormone that controls vasoconstriction and blood pressure. In this review, we provide the general context of the molecular and cellular mechanisms of SARS-CoV-2 infection with a focus on endothelial cells, describe the vasculopathy and coagulopathy syndromes in patients with SARS-CoV-2, and outline current understanding of the underlying mechanistic aspects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.